SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Democratic gains in the midterms and expected control of Congress dominate discussion, with traders viewing the result as a political setback that could weaken Trumps influence and increase scrutiny of his administration. The community is largely bearish on DJT, though some argue the outcome was priced in or that Trump retains leverage through veto power.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democratic midterm gains and the prospect of divided-government gridlock dominate discussion, as SPY reversed an election-related selloff into a sharp rally that caught many bearish traders off guard. Some traders see the result as priced in and market-friendly, while others remain wary of potential AI and data-center regulation and continued volatility.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Democratic midterm gains have fueled trader concerns about increased scrutiny of SpaceXs government contracts, data-center expansion and a potential Tesla tie-up. Some see political risk and possible delays as a lasting headwind, while others call the reaction an overreach and remain bullish on the companys space and AI ambitions.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers quarterly revenue miss and ongoing AI data-center buildout have fueled debate: bears question near-term execution and financing, while bulls point to first HPC lease revenue and long-term contracts. The sharp rebound has prompted oversold-bounce and short-covering speculation, alongside optimism about the companys AI infrastructure plans.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers quarterly results and Q4 outlook dominate discussion, with many traders describing a modest beat but debating adjusted versus GAAP earnings and whether guidance was strong enough. Reactions are split: some see solid business momentum, while others are frustrated that the stock remains weak despite the results.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

A major quarterly earnings beat and raised outlook, fueled by strong AI-server demand, are driving attention to SMCI. Many traders see the results as evidence of growth and an undervalued stock, while others question whether thin margins, cash flow, and lingering credibility concerns justify the muted share reaction; election-related worries about AI infrastructure also add volatility.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected Q3 results and raised full-year outlook, supported by Wegovy pill demand, are driving attention. Bulls see evidence of a growth recovery, while skeptics argue that Lillys competition, pricing pressure and management concerns may limit the stocks response.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs better-than-expected quarterly results and upbeat outlook, driven by strong AI and data-center demand, are the main catalyst. Many traders see the results as evidence of accelerating growth, while others question the valuation, cash generation and whether political or regulatory hurdles could slow data-center expansion.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic midterm gains drove a sharp selloff and then a powerful rebound in QQQ, as traders debated whether the result was a relief rally after uncertainty was priced in or a threat to tech from possible AI and data-center restrictions. Some see divided government as stabilizing for markets, while others remain cautious about regulation and the sustainability of AI-related valuations.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Traders are linking Teslas weakness to reported Democratic gains in the midterms and speculating that greater scrutiny of Elon Musk, government ties, and a potential TeslaSpaceX merger could create headwinds. The discussion is largely bearish, though some traders see the political fears as overblown or a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

Key PointsHe feels it's a clear buy at the current price...

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

Equity

Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.


Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Add LXRX Stock to Your Portfolio Now

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Key PointsLexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs...

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving Average   - Here's What Happened

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average - Here's What Happened...

Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-lexicon-pharmaceuticals-inc-stock...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year High  - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - What's Next...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Novo began the early-stage study in March 2026.</li><li>Results from the trial are due in early 2027.&nbsp;</li><li>Lexicon’s total package under its deal with Novo can reach up to $1 billion in upfront and milestone payments, plus tiered royalties on future sales.</li></ul>Shares of Lexicon Pharmaceuticals (LXRX) edged 1% higher on Monday after the biotech firm announced it earned a third $10 million milestone payment from Danish drugmaker Novo Nordisk (NVO) tied to progress on an experimental oral obesity drug.Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851. This marks the third $10 million development milestone Lexicon has received from Novo in 2026.LX9851 is an oral pill that blocks a protein involved in how the body stores fat and manages energy. It differs from injectable weight-loss drugs like Novo’s Wegovy. Early animal studies suggested it could enhance weight loss when combined with those injectables and help limit rebound gain after stopping them.Novo began the early-stage study in March 2026. It is checking safety, how the drug moves through the body, and early effects in overweight or obese adults. Results are due in the first quarter of 2027.“This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” CEO Mike Exton said. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones.”<h2 class="st-heading-2">Deal Background And Remaining Potential</h2>Novo Nordisk, best known for its weight-loss drug Wegovy, licensed LX9851 from Lexicon in March 2025, primarily to expand its obesity and metabolic disease pipeline. Novo gained full rights to develop, make, and sell LX9851 for any use while Lexicon received $45 million upfront.The total package can reach up to $1 billion in upfront and milestone payments, plus tiered royalties on future sales. With the latest payment, Lexicon has collected $75 million so far—leaving it eligible for roughly $925 million more if the program hits later development, approval, launch, and sales targets.The further payments are not guaranteed and hinge on Novo’s continued success. Royalties would range from the single digits to low double digits of net sales if the drug reaches patients.In June, at a conference, Exton said, "We expect another $10 million from the commencement of the multiple-ascending dose later this year." Novo has indicated that they will move directly into phase II, when satisfaction from both of those studies is achieved, and that would mean another $60 million in the first part of 2027.”As of June 30, Lexicon Pharmaceuticals held $190.6 million in cash, cash equivalents, and short-term investments.<h2 class="st-heading-2">How Did LXRX Retail Traders React?</h2>On Stocktwits, retail sentiment around LXRX stock stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that the company now needs some evidence on LX9851’s efficacy.<stembedurl>https://stocktwits.com/blaack_rules/message/662711491</stembedurl>Another noted the potential for additional funding to flow into the company from the licensing deal.<stembedurl>https://stocktwits.com/Planetpaprika/message/662682390</stembedurl><a href="https://stocktwits.com/symbol/LXRX">LXRX stock</a> has more than doubled year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/citadel-securities-critical-of-treasury-s-buyback-plans-calls-it-financial-repression/cZYKnH1RJFB">Citadel Securities Critical Of Treasury’s Buyback Plans, Calls It ‘Financial Repression’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Lexicon Pharmaceuticals logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Novo began the early-stage study in March 2026.Results from the trial are due in early 2027. Lexicon’s total package under its deal with Novo can reach up to $1 billion in upfront and milestone payments, plus tiered royalties on future sales.

Current Price	$1.46
Prev Close	$1.44
Open	$1.44
Dividend Yield	0.00%
50-Day Moving Average	$1.85
Beta	1.62
Avg. Volume	1.97M
PE Ratio	-9.54

52-Week High	$2.68
52-Week Low	$1.10
Market Capitalization	$640.74M
EPS (Annual)	-$0.1387
Price to Book	3.72
Revenue Per Employee	$614,851.85

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXRX Fundamentals